-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.
Event: | Cantor Neurology & Psychiatry Conference – October 6th - 7th | |
Panel: | "Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise." Friday, October 7th at 10:10-11:10 AM PT (1:10-2:10 PM ET) | |
1x1 Meetings: | Management will be available for one-on-one meetings October 6th & 7th |
The panel presentation will be available only to conference participants and will not be webcast. To schedule a virtual or in-person meeting with Lumos Pharma management during the conference, please contact your Cantor sales representative.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.
得克薩斯州奧斯汀,9月環球新聞網2022年3月26日電生物製藥公司Lumos Pharma,Inc.(納斯達克市場代碼:LUMO)宣佈,Lumos製藥公司管理層將參加一個小組討論,並在10月份的坎託神經學和精神病學會議上主持一對一會議。該公司推出了一種新的口服治療候選藥物LUM-201,正在進行兒科生長激素缺乏症的第二階段臨牀試驗。
Event: | Cantor Neurology & Psychiatry Conference – October 6th - 7th | |
Panel: | "Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise." Friday, October 7th at 10:10-11:10 AM PT (1:10-2:10 PM ET) |
|
1x1 Meetings: | Management will be available for one-on-one meetings October 6th & 7th |
活動: | 康託神經學和精神病學會議--10月6日這是 - 7這是 | |
評審團: | “電路中斷。調節神經內分泌系統以重建平衡。” 10月7日(星期五)這是太平洋時間上午10:10-11:10(東部時間下午1:10-2:10) |
|
1x1會議: | 管理層將於10月6日出席一對一會議這是 & 7這是 |
The panel presentation will be available only to conference participants and will not be webcast. To schedule a virtual or in-person meeting with Lumos Pharma management during the conference, please contact your Cantor sales representative.
小組演講將僅對與會者開放,不會進行網絡直播。要在會議期間安排與Lumos Pharma管理層的虛擬或面對面會議,請聯繫您的康託銷售代表。
About Lumos Pharma
關於Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit
Lumos製藥公司是一家臨牀階段的生物製藥公司,專注於罕見疾病治療藥物的開發和商業化。Lumos Pharma是由一個在罕見疾病藥物開發方面擁有長期經驗的管理團隊創立並領導的,並從領先的醫療保健投資者那裏獲得了早期資金,其中包括由Blackstone生命科學管理的基金Deerfield Management、羅氏風險基金、New Enterprise Associates(NEA)、SantéVentures和UCB。Lumos Pharma的主要候選藥物是Lum-201,這是一種口服生長激素刺激性小分子,目前正在進行第二階段臨牀試驗、OraGrowtH210試驗、PK/PD試驗、OraGrowtH212試驗和Switch試驗,即治療兒童生長激素缺乏症(PGHD)的OraGrowtH213試驗。如果FDA批准,Lum-201將提供一種口服替代重組生長激素注射的方法,否則PGHD患者將接受多年的治療。Lum-201在美國和歐盟都獲得了孤兒藥物稱號。欲瞭解更多信息,請訪問
Investor & Media Contact:
投資者和媒體聯繫人:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
麗莎·米勒
Lumos Pharma投資者關係
512-792-5454
郵箱:ir@Lumos-pharma.com
Source: Lumos Pharma, Inc.
消息來源:Lumos製藥公司
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧